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Vitamin D analogs: From renal bone disease to osteoporosis. The pathogenesis of renal osteodystrophy is complex
The history of the use of vitamin D metabolites and analogs and multifactorial [6, 7]. The most widely prevalent type
in clinical medicine began with their use in renal bone disease of bone disease is hyperparathyroidism. It is now evidentfollowing the appreciation that the kidney is the major site of
that hyperparathyroidism develops early in the coursethe la-hydroxylase of vitamin D. In the presence of advanced
of progressive chronic renal failure and that this is atrenal failure, production of calcitriol is impaired and treatment
is viewed conceptually as a hormone replacement therapy. least in part due to hypocalcemia [8]. The cause of hypo-
Since then, there has been much interest in the rationale for calcemia has been a source of controversy. The two most
the use of such compounds in osteoporosis. Arguments have popular ideas have been that either phosphate retentionbeen variously forwarded that osteoporosis is in part due to
[9, 10] or impaired calcemic responses to parathyroideither a defective la-hydroxylase occurring at menopause or
in later life or to target tissue resistance to calcitriol; some hormone [11, 12] are responsible. Both these mechanisms
argue that disturbances in vitamin D metabolism are irrelevant may be mediated by disturbances in vitamin D metabolism.
to osteoporosis, being either a consequence of aging or a result, In patients with mild renal impairment (glomerular
not a cause, of osteoporosis itself. This paper reviews these
filtration rate 55–65 ml/min) severe dietary phosphatevarious issues and explores the differences and similarities be-
restriction induces a significant increase in serum calcitrioltween the pathogenesis of renal bone disease and osteoporosis.
concentration, intestinal absorption of calcium and se-
rum calcium concentration together with a significant fall
in serum parathyroid hormone [12, 13]. These changesRenal bone disease is more or less ubiquitous in pa-
occurred despite the fact that patients were hypophos-tients with end-stage chronic renal failure, whether they
phatemic rather than hyperphosphatemic and had basalbe maintained with hemodialysis or with continuous am-
serum calcitriol values within the normal range. One inter-bulatory peritoneal dialysis. The prevalence of renal
bone disease at the start of dialysis is highest when histo- pretation of these data is that intracellular rather than
logic criteria are utilized, intermediate with radiographic extracellular phosphate accumulation impairs calcitriol
criteria, and lowest with clinical criteria [1]. There is, production early in the course of renal failure. Serum
however, a close correlation between symptoms, radio- calcitriol concentrations, although normal in the sense
graphic abnormalities, and histologic findings, and im- that they are comparable to those seen in normocalcemic
provements in the one are associated with favorable non-uremic subjects, are inappropriately low for the de-
changes in the other [2]. The severity of renal bone gree of hyperparathyroidism. Thus, a phosphate-induced
disease increases progressively with time on dialysis. reduction in the capacity of the kidney to increase calcitriol
Abnormalities in bone histology may be detected rela- production could have a central role in the genesis of
tively early in the natural history of chronic renal failure hypocalcemia and hyperparathyroidism. The predilection
and are found when the creatinine clearance values fall of the young and of patients with tubulointerstitial forms
below 60 ml/min [3]. Patients who are at particular risk of of renal disease to develop renal osteodystrophy may be
developing renal bone disease include children, women, related therefore to decreased availability of calcitriol
those with a long history of renal impairment, and those because of preferential destruction of the cells synthesiz-
with predominantly tubulointerstitial forms of renal dis- ing the 1a-hydroxylase [4].
ease [4]. The prevalence of renal osteodystrophy varies Hypocalcemia is not, however, the sole stimulus for
markedly between centers in part due to differences in parathyroid hormone secretion [14, 15]. Phosphate may
approaches to therapeutics, but this variation probably directly stimulate the secretion of parathyroid hormone
results more from differences in the diagnostic criteria (PTH). In addition, calcitriol deficiency increases skele-
used to identify bone disease [5, 6]. tal resistance to the effects of parathyroid hormone, and
increases parathyroid cell proliferation and secretion,
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crucial role for calcitriol deficiency in the genesis of hyper- 1999 by the International Society of Nephrology
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Table 1. Histologic findings on bone biopsy in 176 patients withparathyroid bone disease provides a sound rationale or
moderate chronic renal failure (creatinine clearance
its use in the management of renal bone disease. 15–50 ml/min)
Histologic findings Number %
USE OF VITAMIN D AND RELATED Osteitis fibrosa 129 73
Osteitis fibrosa and osteomalacia 33 19COMPOUNDS IN RENAL BONE DISEASE
Osteomalacia alone 1 ,1
A variety of vitamin D compounds is available for use Aluminum staining of bone 2 1
Adynamic bone lesions 9 5in chronic renal failure. These include the parent vitamins
califerol and cholecalciferol, dihydrotachysterol, calcitriol From Hamdy et al [31].
and alfacalcidol. A great deal of interest has focused on
the la-hydroxylated derivatives (calcitriol and alfacalci-
dol) since they bypass the metabolic block caused by
that it is the hypercalcemia rather than the vitamin Duremia—namely a deficiency in the la hydroxylase en-
that is toxic. Irrespective of the mechanisms, these con-zyme.
cerns have limited the widespread use of vitamin-D re-All the vitamin D-like compounds appear to be effec-
lated compounds to alter the natural history of renaltive in augmenting calcium absorption, relieving symp-
bone disease in patients with renal failure, but not yettoms of bone pain and muscle weakness, and increasing
requiring renal replacement treatment.serum calcium in the majority of patients [23–26]. They
We have undertaken a double-blind, prospective, ran-suppress elevated serum values of alkaline phosphatase,
domized, placebo-controlled study to examine the effectsserum parathyroid hormone, and correct radiographic
of alfacalcidol in patients with mild to moderate renalabnormalities. Skeletal deformity in the young can prob-
failure [31]. By limiting the maximum dose to 1 mg daily,ably be prevented and growth partially restored [27].
we showed beneficial effects on both hyperparathyroidBoth osteitis fibrosa and osteomalacia appear to respond
bone disease and osteomalacia in patients given alfacalci-to these compounds. There is a correlation between his-
dol compared to the responses seen in placebo-treatedtologically induced changes with treatment and symp-
individuals. Although hypercalcemia occurred more fre-tomatic improvements [2].
quently in alfacalcidol-treated patients the incidence wasThere is no evidence that calcitriol, alfacalcidol, or
relatively low, generally mild and readily treated by de-other agents have particular therapeutic actions not also
creasing the dose. Patients were selected for inclusionpossessed by the parent vitamin. The advantages of the
into the study by the absence of overt bone disease. Inla-hydroxylated derivatives lie in the ease with which
other words, they had normal radiographs and a normaldoses are titrated according to requirements and the
activity of alkaline phosphatase. The end points thatrapidity with which toxic effects are reversed on stopping
were studied were the effects of intervention on quantita-treatment [28]. Treatment with vitamin D or its metabo-
tive histology of bone. At the end of treatment (2 yearslites is not without risk. Prolonged increases in plasma
or until dialysis was required), there was a significantcalcium and phosphate give rise to extraskeletal calcifi-
difference in the severity of bone disease between thecation. Patients with pre-existing hypercalcemia should
two wings in favor of alfacalcidol.be treated cautiously, if at all, since such patients often
Despite an upward drift in serum calcium at a consis-respond poorly to treatment [24]. Prolonged hypercalce-
tently higher level in alfacalcidol-treated patients, theremia may also impair renal function, sometimes irrevers-
was no deleterious effect on the progression of renalibly, and there has been concern that vitamin D com-
failure, as judged by serum creatinine or endogenouspounds may themselves by nephrotoxic. For this reason
creatinine clearance. All patients showed a deteriorationthe la-hydroxylated derivatives have been principally
of renal function as expected, but this was equal in pla-used in the management of renal bone disease in patients
cebo compared to alfacalcidol-treated patients. The safetyon dialysis.
profile of this regimen suggests that alfacalcidol and re-There is much less experience with the use of vitamin D
lated compounds might be more widely used in the man-compounds in early renal failure. The results of 20 open
agement of hyperparathyroid bone diseaseand control studies in early renal failure on a total of
A further interesting finding in this study was that thesome 220 patients were reviewed in 1992 [29]. Whereas
prevalence of hyperparathyroid bone disease at the timebeneficial effects of calcitriol on renal bone disease were
of study entry was remarkably high. Three-quarters offound, the incidence of hypercalcemia was high, and
patients had histologic evidence of hyperparathyroid boneserious reservations were raised about the possible ad-
disease despite a creatinine clearance on average of 40verse effects of treatment on renal function. There is
ml/min (Table 1). The study described above suggestssome uncertainty as to whether deterioration of renal
therefore that alfacalcidol was utilized to treat mild renalfunction is a consequence of hypercalcemia or a direct
effect of vitamin D [30]. Most evidence would suggest bone disease rather than to prevent its occurrence de novo.
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HYPERPARATHYROID BONE DISEASE OF may be due to dietary deficiency, decreased exposure to
sunlight, or decreased cutaneous production of vitamin D.THE ELDERLY
Although osteomalacia may occur in the elderly, theMany studies have suggested that vitamin D metabo-
view that its prevalence is high in the aged communitylism is disturbed in osteoporosis. Several studies have
is largely dependent upon inadequate criteria for its diag-shown decreased serum concentrations of calcitriol in
nosis. Where diagnosis is based on more rigorous histo-the early postmenopausal period, and it has been sug-
logic criteria, osteomalacia is considered to be relativelygested that this gives rise to malabsorption of calcium
rare. In contrast, both histologic and biochemical studies[32], which, in view of the increased requirement for
suggest that skeletal turnover increases through later life;calcium after the menopause, accelerates osteoporotic
a great deal of biochemical evidence, including serumbone loss. Because estrogens may stimulate the synthesis
values of intact parathyroid hormone, renal tubular reab-of calcitriol, at least in vitro, estrogen withdrawal has
sorption of phosphate, and nephrogenous cyclic AMP,been thought to be the signal for decreased production
suggests that skeletal turnover is mediated at least inof calcitriol.
part by PTH [36]. There are several possible mechanismsThis mechanism is not, however, the only means possi-
for the induction of secondary hyperparathyroidism inble to account for calcium malabsorption. It is equally
the elderly. These include deficient nutritional intakeplausible that estrogen deficiency directly causes bone
of vitamin D, target tissue resistance to vitamin D andloss, which in turn infuses the extracellular compartment
disturbances in vitamin D metabolism secondary towith calcium and that this in turn decreases the secretion
changes in renal function with age. In populations studiesof PTH and the synthesis of calcitriol. Thus, the intestinal
of persons over the age of 70 years, about 20% have amalabsorption is a consequence of bone loss and not its
creatinine clearance below 50 ml/min—the criteria thatcause.
we have utilized in studies for the prevention of renalWith advancing years, however, lower values for calci-
bone disease [31]. The relative importance of renal fail-triol and increased secretion of PTH are consistently
ure and other factors is, however, uncertain.
found [32]. Both changes could well be due to the decline
in renal function with age, suggesting some parallel be-
USE OF VITAMIN D AND ANALOGStween bone disease of the elderly and mild chronic renal
IN OSTEOPOROSISfailure. Indeed, on the basis of population studies hyper-
parathyroidism is common. This suggests that abnormali- Despite these uncertainties, there is now accumulating
ties in vitamin D metabolism occur with aging. The various evidence from prospective and retrospective studies that
mechanisms whereby secondary hyperparathyroidism the administration of vitamin D or exposure to sunlight
might occur are very similar for those describing the decreases bone loss in the elderly and is associated with
pathogenesis of renal bone disease [33]. a decrease in the risk of hip and other osteoporosis-related
The question arises how often secondary hyperpara- fractures [37–39]. In population studies of women be-
thyroidism is complicated by privational deficiency of tween the ages of 45 and 65 years, a significant correlation
vitamin D, and if so, whether it contributes to fracture has been observed between serum calcidiol and bone
risk. Vitamin D deficiency is a well recognized cause of mineral density [40]. The proportion of the variance in
fractures. The frequency with which it occurs is more bone mineral density explained by vitamin D status is
difficult to judge because the distinction between hyper- low (less than 5%), but this has been largely determined
parathyroid bone disease and mild vitamin D deficiency in the young. For this reason, changes in renal function
is not straightforward. Many histologic studies of patients may be more important in the elderly.
with hip fractures that have reported a high prevalence The comparative effects of vitamin D and the la-
of osteomalacia do not make this distinction. Where this hydroxylated derivatives have not been adequately eval-
distinction is made, for example by measuring the osteoid uated in osteoporosis. Alfacalcidol and calcitriol have
seam width, the osteoid seam width has been shown to been tested largely in younger individuals with estab-
be normal [34] or increased [35]. A further problem in lished osteoporosis, notably those with vertebral frac-
distinguishing hyperparathyroidism due to renal causes tures. Studies of calcitriol have given variable results,
and from nutritional causes is that the sensitivity and perhaps related to problems with trial methodology that
specificity of calcidol measurements are poor. Although have only recently been identified. In contrast, there is
calcidol values are lower than controls in some series of more consistent evidence that alfacalcidol is associated
patients with hip fracture [34], this is by no means an with a decrease in vertebral fracture frequency, but nei-
invariable finding. ther have been tested in the context of hip fracture [41].
A component of the rationale for the use of vitamin D Moreover, therapeutic strategies for the use of the me-
and related compounds in the elderly therefore concerns tabolites of vitamin D have been based on delivering
the maximum tolerated dose, whereas regimens withthe question of coexisting vitamin D deficiency. This
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